Pseudo-mannosylated DC-SIGN Ligands as potential adjuvants for HIV vaccines

Angela Berzi, Norbert Varga, Sara Sattin, Patrizio Antonazzo, Mara Biasin, Irene Cetin, Daria Trabattoni, Anna Bernardi, Mario Clerici

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The development of new and effective adjuvants may play a fundamental role in improving HIV vaccine efficacy. New classes of vaccine adjuvants activate innate immunity receptors, notably toll like receptors (TLRs). Adjuvants targeting the C-Type lectin receptor DC-SIGN may be alternative or complementary to adjuvants based on TRL activation. Herein we evaluate the ability of the glycomimetic DC-SIGN ligand Polyman 19 (PM 19) to modulate innate immune responses. Results showed that PM 19 alone, or in combination with TLR agonists, induces the expression of cytokines, β chemokines and co-stimulatory molecules that may, in turn, modulate adaptive immunity and exert anti-viral effects. These results indicate that the suitability of this compound as a vaccine adjuvant should be further evaluated.

Original languageEnglish
Pages (from-to)391-403
Number of pages13
JournalViruses
Volume6
Issue number2
DOIs
Publication statusPublished - 2014

Fingerprint

AIDS Vaccines
Toll-Like Receptors
Innate Immunity
Vaccines
Ligands
C-Type Lectins
Adaptive Immunity
Chemokines
Cytokines
DC-specific ICAM-3 grabbing nonintegrin

Keywords

  • Adjuvant
  • DC-SIGN
  • Glycomimetic compounds
  • HIV-1
  • Innate immunity
  • Vaccine

ASJC Scopus subject areas

  • Infectious Diseases
  • Virology

Cite this

Berzi, A., Varga, N., Sattin, S., Antonazzo, P., Biasin, M., Cetin, I., ... Clerici, M. (2014). Pseudo-mannosylated DC-SIGN Ligands as potential adjuvants for HIV vaccines. Viruses, 6(2), 391-403. https://doi.org/10.3390/v6020391

Pseudo-mannosylated DC-SIGN Ligands as potential adjuvants for HIV vaccines. / Berzi, Angela; Varga, Norbert; Sattin, Sara; Antonazzo, Patrizio; Biasin, Mara; Cetin, Irene; Trabattoni, Daria; Bernardi, Anna; Clerici, Mario.

In: Viruses, Vol. 6, No. 2, 2014, p. 391-403.

Research output: Contribution to journalArticle

Berzi, A, Varga, N, Sattin, S, Antonazzo, P, Biasin, M, Cetin, I, Trabattoni, D, Bernardi, A & Clerici, M 2014, 'Pseudo-mannosylated DC-SIGN Ligands as potential adjuvants for HIV vaccines', Viruses, vol. 6, no. 2, pp. 391-403. https://doi.org/10.3390/v6020391
Berzi A, Varga N, Sattin S, Antonazzo P, Biasin M, Cetin I et al. Pseudo-mannosylated DC-SIGN Ligands as potential adjuvants for HIV vaccines. Viruses. 2014;6(2):391-403. https://doi.org/10.3390/v6020391
Berzi, Angela ; Varga, Norbert ; Sattin, Sara ; Antonazzo, Patrizio ; Biasin, Mara ; Cetin, Irene ; Trabattoni, Daria ; Bernardi, Anna ; Clerici, Mario. / Pseudo-mannosylated DC-SIGN Ligands as potential adjuvants for HIV vaccines. In: Viruses. 2014 ; Vol. 6, No. 2. pp. 391-403.
@article{19f128a68a29484b809228652b0600e1,
title = "Pseudo-mannosylated DC-SIGN Ligands as potential adjuvants for HIV vaccines",
abstract = "The development of new and effective adjuvants may play a fundamental role in improving HIV vaccine efficacy. New classes of vaccine adjuvants activate innate immunity receptors, notably toll like receptors (TLRs). Adjuvants targeting the C-Type lectin receptor DC-SIGN may be alternative or complementary to adjuvants based on TRL activation. Herein we evaluate the ability of the glycomimetic DC-SIGN ligand Polyman 19 (PM 19) to modulate innate immune responses. Results showed that PM 19 alone, or in combination with TLR agonists, induces the expression of cytokines, β chemokines and co-stimulatory molecules that may, in turn, modulate adaptive immunity and exert anti-viral effects. These results indicate that the suitability of this compound as a vaccine adjuvant should be further evaluated.",
keywords = "Adjuvant, DC-SIGN, Glycomimetic compounds, HIV-1, Innate immunity, Vaccine",
author = "Angela Berzi and Norbert Varga and Sara Sattin and Patrizio Antonazzo and Mara Biasin and Irene Cetin and Daria Trabattoni and Anna Bernardi and Mario Clerici",
year = "2014",
doi = "10.3390/v6020391",
language = "English",
volume = "6",
pages = "391--403",
journal = "Viruses",
issn = "1999-4915",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "2",

}

TY - JOUR

T1 - Pseudo-mannosylated DC-SIGN Ligands as potential adjuvants for HIV vaccines

AU - Berzi, Angela

AU - Varga, Norbert

AU - Sattin, Sara

AU - Antonazzo, Patrizio

AU - Biasin, Mara

AU - Cetin, Irene

AU - Trabattoni, Daria

AU - Bernardi, Anna

AU - Clerici, Mario

PY - 2014

Y1 - 2014

N2 - The development of new and effective adjuvants may play a fundamental role in improving HIV vaccine efficacy. New classes of vaccine adjuvants activate innate immunity receptors, notably toll like receptors (TLRs). Adjuvants targeting the C-Type lectin receptor DC-SIGN may be alternative or complementary to adjuvants based on TRL activation. Herein we evaluate the ability of the glycomimetic DC-SIGN ligand Polyman 19 (PM 19) to modulate innate immune responses. Results showed that PM 19 alone, or in combination with TLR agonists, induces the expression of cytokines, β chemokines and co-stimulatory molecules that may, in turn, modulate adaptive immunity and exert anti-viral effects. These results indicate that the suitability of this compound as a vaccine adjuvant should be further evaluated.

AB - The development of new and effective adjuvants may play a fundamental role in improving HIV vaccine efficacy. New classes of vaccine adjuvants activate innate immunity receptors, notably toll like receptors (TLRs). Adjuvants targeting the C-Type lectin receptor DC-SIGN may be alternative or complementary to adjuvants based on TRL activation. Herein we evaluate the ability of the glycomimetic DC-SIGN ligand Polyman 19 (PM 19) to modulate innate immune responses. Results showed that PM 19 alone, or in combination with TLR agonists, induces the expression of cytokines, β chemokines and co-stimulatory molecules that may, in turn, modulate adaptive immunity and exert anti-viral effects. These results indicate that the suitability of this compound as a vaccine adjuvant should be further evaluated.

KW - Adjuvant

KW - DC-SIGN

KW - Glycomimetic compounds

KW - HIV-1

KW - Innate immunity

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=84893333504&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893333504&partnerID=8YFLogxK

U2 - 10.3390/v6020391

DO - 10.3390/v6020391

M3 - Article

C2 - 24473338

AN - SCOPUS:84893333504

VL - 6

SP - 391

EP - 403

JO - Viruses

JF - Viruses

SN - 1999-4915

IS - 2

ER -